Literature DB >> 6469932

Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration.

M C Meyer, A B Straughn, M W Lo, W L Schary, C C Whitney.   

Abstract

Healthy male volunteers (N = 24) participated in a four-way crossover study to compare the rate and extent of absorption of naltrexone after administration of 50 mg tablets as 50, 100, and 200 mg doses and a 10 mg/ml reference syrup. A high-performance liquid chromatographic method was employed to measure naltrexone and 6-beta-naltrexol in plasma and urine. Compared to the syrup, the 50 mg tablets were absorbed more slowly but equally well. There was excellent linearity between the administered dose and the area under the plasma concentration-time profile, as well as total urinary recovery of both drug and metabolite. The mean half-lives for naltrexone and beta-naltrexol were approximately 4 and 12 hours, respectively. The fraction of drug reaching the systemic circulation was estimated to be 5% of the administered dose because of extensive first-pass metabolism. Less than 1% of the dose was excreted in the urine as naltrexone after 48 hours, while 25% was recovered as unconjugated beta-naltrexol. The renal clearance of naltrexone and beta-naltrexol was approximately 127 ml/min and 283 ml/min, respectively. The total systemic clearance for naltrexone was approximately 94 L/hr.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6469932

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  41 in total

1.  Bioavailability prediction based on molecular structure for a diverse series of drugs.

Authors:  Joseph V Turner; Desmond J Maddalena; Snezana Agatonovic-Kustrin
Journal:  Pharm Res       Date:  2004-01       Impact factor: 4.200

2.  Reduction of conditioned pain modulation in humans by naltrexone: an exploratory study of the effects of pain catastrophizing.

Authors:  Christopher D King; Burel Goodin; Lindsay L Kindler; Robert M Caudle; Robert R Edwards; Nikolaus Gravenstein; Joseph L Riley; Roger B Fillingim
Journal:  J Behav Med       Date:  2012-04-26

3.  Factor structure and validity of the Medication Adherence Questionnaire (MAQ) with cigarette smokers trying to quit.

Authors:  Benjamin A Toll; Sherry A McKee; Daniel J Martin; Peter Jatlow; Stephanie S O'Malley
Journal:  Nicotine Tob Res       Date:  2007-05       Impact factor: 4.244

Review 4.  Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users.

Authors:  D I Quinn; A Wodak; R O Day
Journal:  Clin Pharmacokinet       Date:  1997-11       Impact factor: 6.447

5.  Naltrexone Maintenance: Effect on Morphine Sensitivity in Normal Volunteers.

Authors:  James W Cornish; David Henson; Sanford Levine; Joseph Volpicelli; Charles E Inturrisi; Byron C Yoburn; Charles P O'Brien
Journal:  Am J Addict       Date:  1993

6.  Vehicle composition influence on the microneedle-enhanced transdermal flux of naltrexone hydrochloride.

Authors:  Mikolaj Milewski; Audra L Stinchcomb
Journal:  Pharm Res       Date:  2010-06-25       Impact factor: 4.200

7.  Comparison of naltrexone, 6alpha-naltrexol, and 6beta-naltrexol in morphine-dependent and in nondependent rhesus monkeys.

Authors:  Jun-Xu Li; Lance R McMahon; Charles P France
Journal:  Psychopharmacology (Berl)       Date:  2007-09-16       Impact factor: 4.530

8.  Separate and combined impact of acute naltrexone and alprazolam on subjective and physiological effects of oral d-amphetamine in stimulant users.

Authors:  Katherine R Marks; Joshua A Lile; William W Stoops; Craig R Rush
Journal:  Psychopharmacology (Berl)       Date:  2014-01-25       Impact factor: 4.530

Review 9.  Potential uses of naltrexone in emergency department patients with opioid use disorder.

Authors:  Evan Stuart Bradley; David Liss; Stephanie Pepper Carreiro; David Eric Brush; Kavita Babu
Journal:  Clin Toxicol (Phila)       Date:  2019-03-04       Impact factor: 4.467

10.  Effects of naltrexone on pain sensitivity and mood in fibromyalgia: no evidence for endogenous opioid pathophysiology.

Authors:  Jarred W Younger; Alex J Zautra; Eric T Cummins
Journal:  PLoS One       Date:  2009-04-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.